Compare RNP & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNP | CDNA |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | 2007 |
| Metric | RNP | CDNA |
|---|---|---|
| Price | $21.06 | $22.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 76.1K | ★ 583.8K |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $455.40 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $19.27 | $10.96 |
| 52 Week High | $22.99 | $23.24 |
| Indicator | RNP | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 65.92 |
| Support Level | $20.44 | $15.80 |
| Resistance Level | $21.24 | $22.89 |
| Average True Range (ATR) | 0.28 | 0.95 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 62.10 | 90.52 |
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.